Join Immunovia for an Insightful Q4 Presentation
Immunovia AB is gearing up to present its full year results for 2024, and everyone interested in their progress is encouraged to attend the upcoming webcast scheduled for February. Analysts, investors, and members of the media will have the opportunity to learn about the company's latest developments and advancements in its mission to improve pancreatic cancer diagnostics.
Details of the Webcast Teleconference
The presentation will take place on February 25 at 15:00 CET. Participants will be able to access the webcast via Immunovia's official website. Jeff Borcherding, the CEO and President, alongside Karin Almqvist Liwendahl, the CFO, will walk attendees through the results and innovations the company has made in the field of diagnostics.
How to Join the Presentation
Everyone interested in joining the presentation via phone can do so by calling in a few minutes before it starts. Below are the numbers to use based on your location:
Sweden: +46 (0)8 5051 0031
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (631) 570 56 13
After the Presentation
Following the live presentation, a recording will be made available on the Immunovia website. This is a fantastic option for those who cannot attend the live session or wish to revisit the insights shared.
Contact Information for More Details
For further inquiries, contact Karin Almqvist Liwendahl, CFO, at +46 70 911 56 08. Immunovia is dedicated to creating accessible information for everyone interested in their work and impact in the healthcare space.
The Mission and Vision of Immunovia
Immunovia AB is a pioneering diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company has developed innovative blood-based tests designed to identify individuals at high risk of developing pancreatic cancer by detecting specific proteins and antibodies.
Immunovia collaborates with healthcare providers, top experts, and patient advocacy groups to ensure that their tests become available for individuals who are at heightened risk of this devastating disease. In doing so, they aim to alter the landscape of pancreatic cancer diagnosis and management.
Market Opportunities and Potential
In the USA, which represents the largest market for detecting pancreatic cancer, Immunovia estimates that approximately 1.8 million individuals could benefit from annual surveillance testing for this disease. This estimate underscores a significant opportunity for the company to expand its reach and impact through its advanced testing methods.
Immunovia's shares are traded under the ticker IMMNOV on Nasdaq Stockholm, reflecting its commitment to transparency and growth within the financial market. Investors and stakeholders are encouraged to stay updated with Immunovia's progress through their website.
Frequently Asked Questions
What is the date and time of the Q4 presentation?
The Q4 presentation will be held on February 25 at 15:00 CET.
Who will be presenting during the webcast?
The presentation will be led by Jeff Borcherding, CEO, and Karin Almqvist Liwendahl, CFO.
How can I access the presentation?
Participants can join the webcast via Immunovia's official website where the presentation and slides will be available.
Will there be a recording of the presentation?
Yes, a recording of the presentation will be available on Immunovia's website after the live session.
What is Immunovia's mission?
Immunovia aims to increase survival rates for pancreatic cancer patients by developing early detection methods through innovative diagnostic tests.
